Background. Cases of severe and fatal liver injury were reported after a 2-month course of rifampin-pyrazinamide therapy was recommended in 2000 as an alternative to isoniazid for treatment of latent tuberculosis infection. We estimated rates of rifampin-pyrazinamide-associated liver injury and compared these with historical rates for isoniazid.
Persons exposed to contagious tuberculosis (TB) may become infected with Mycobacterium tuberculosis and later develop TB disease. The risk of progression to TB safety and efficacy came from 3 randomized clinical trials involving HIV-infected persons [5] [6] [7] . The results became the scientific basis for recommending rifampin-pyrazinamide therapy for HIV-uninfected persons. A multicenter study of the programmatic feasibility of rifampin-pyrazinamide therapy was initiated in 2000 [8] , and a patient involved in this project died of liver injury [9] . Following additional reports of liver injury, revised interim guidelines were issued in mid-2001 [10] ; nevertheless, adverse reactions continued [11] .
LTBI and its treatment are not reportable conditions in most TB-control jurisdictions. Therefore, the number of patients who initiated rifampin-pyrazinamide therapy-and therefore, the rate of adverse events-remained unknown. We estimated the rates by surveying TB-control personnel and other health care providers about initiations of rifampin-pyrazinamide treatment and subsequent liver injuries, hospital admissions, and deaths. To determine whether adverse events resulted when other providers prescribed rifampin-pyrazinamide therapy, we also searched a linked database of commercial pharmacy claims and medical claims.
PATIENTS AND METHODS

Passive Surveillance for Adverse Events
The initial US-published report of rifampin-pyrazinamide-associated hepatitis requested additional similar reports [9] , and this request was repeated in updates [10] [11] [12] . We recorded demographic and clinical information from each report on an abstraction form. In collaboration with state and local TBcontrol officials, CDC epidemiologists confirmed hospitalizations and deaths with on-site reviews.
Active Surveillance for Adverse Events
In mid-2002, we retrospectively surveyed for cases of rifampinpyrazinamide-associated liver injury and for the number of patients who initiated rifampin-pyrazinamide therapy (i.e., denominator data). This required establishing a national sampling frame of providers who prescribed rifampin-pyrazinamide.
Institutional review. The protocol for this survey underwent CDC ethics review and was deemed to be an urgent public health response and not to be human subjects research.
Sampling frame. In December 2001, we sent a letter to the directors of all of the 50 state TB programs and the 10 large city TB programs that receive federal categorical funding for TB control. The letter reviewed the public health issues and our strategy for estimating hepatitis rates [9, 10, 13 ]. An enclosed questionnaire requested a list of health care programs and providers prescribing rifampin-pyrazinamide. We contacted each entity to determine who should be surveyed.
Survey. In October 2002, we mailed the survey after pilot testing it in 9 states. The survey covered 3 consecutive periods: 1 January 2000-30 April 2001 (period 1, ending with the first publication of the hepatitis incidents [9] ), 1 May 2001-31 August 2001 (period 2, ending with the publication of revised guidance [10] ), and 1 September 2001-30 June 2002 (period 3, ending with the inception of the survey) [14] . We asked respondents to describe their setting (e.g., county jail) and to confirm which LTBI treatment regimens were used. We made 3 attempts to contact nonresponders by March 2003.
For each of the 3 periods, we requested the following aggregate counts: total number of candidates eligible for treatment of LTBI with any drug regimen; number of patients for whom daily rifampin-pyrazinamide treatment was initiated; number of patients for whom twice-weekly rifampin-pyrazinamide treatment was initiated; number of patients for whom rifampinpyrazinamide treatment was stopped because of asymptomatic elevated serum aspartate aminotransferase (AST) levels (defined as 15 times upper limit of normal, with or without elevated serum bilirubin levels); number of patients for whom rifampinpyrazinamide treatment was stopped because of symptoms of hepatitis (i.e., progressive onset of anorexia, nausea, vomiting, or jaundice); number patients admitted to the hospital for treatment of liver injury within 1 month after administration of the last rifampin-pyrazinamide dose; number of patients who died of liver injury (within 1 month after the last known rifampinpyrazinamide dose was administered); and number of patients who completed rifampin-pyrazinamide therapy. Patient-specific data (e.g., sex and age) were not requested.
Pharmacy Claims Data
We searched the Verispan proprietary electronic reimbursement claims databases to determine whether rifampin-pyrazinamideassociated adverse events occurred in patients whose cases were not captured in our survey. Verispan collects a data warehouse of Health Insurance Portability and Accountability Act of 1996 compliant, standardized, patient-centric claims. For the period 1 January 2000-30 April 2002, the database contained unidentified, patient-linkable claims from 109 million patients, who contributed 2.4 billion claims (∼16% of the electronic claims volume in the United States). These claims arose from ∼38,000 pharmacies, ∼680,000 providers, and ∼4400 hospitals. Retail pharmacy prescriptions included purchases by third-party payers (including Medicare and Medicaid) and cash.
To exclude patients treated for TB disease, the search targeted prescriptions for rifampin and pyrazinamide and no other antituberculosis medications (antituberculosis medications included isoniazid, ethambutol, streptomycin, para-aminosalicylic acid, ethionamide, cycloserine, capreomycin, kanamycin, and thiacetazone). For each patient who received a prescription for rifampin-pyrazinamide, we searched for medical claims made during the period from 7 days after receiving rifampinpyrazinamide therapy to 90 days later. Medical claims with International Classification of Diseases, Ninth Revision (ICD-9), NOTE. The total number of sites that used a daily rifampin-pyrazinamide regimen (81 sites) is 1 less than the total given in table 1 (np82 any use of daily rifampin-pyrazinamide), because 1 site provided no data other than which LTBI regimens were used.
a Reported number of patients who initiated rifampin-pyrazinamide therapy among a total of 127,996 candidates with LTBI who were eligible for therapy during the study period.
codes associated with liver diseases or drug adverse effects prompted a telephone interview of the treating physicians to determine whether the claim was rifampin-pyrazinamide-associated and whether the patient was admitted to a hospital or died. The ICD-9 codes used in the Verispan search were 7905 (other or nonspecified abnormal serum enzyme levels), 7051 (acute unspecified hepatitis C without mention of hepatic coma), and 7904 (nonspecified elevation of levels of transaminase/lactic dehydrogenase).
Adverse Event Reporting System
The United States Food and Drug Administration (FDA) searched the Adverse Event Reporting System for events associated with rifampin and pyrazinamide administered without isoniazid (to exclude patients treated for TB disease), 1 January 2000-30 June 2002.
Data Management and Analysis
We maintained survey responses in a Microsoft Access database (Microsoft). A x 2 test for trend was used to examine whether rifampin-pyrazinamide use (yes vs. no) was related to statespecific TB incidence (categorized as р3.5, 3.6-5.8, and 15.8 cases per 100,000 population) [15] . The rates of asymptomatic AST levels 15 times the upper limit of normal, hepatitis, hospitalization, and death were calculated using adverse event counts from the survey as numerators and the numbers patients who initiated rifampin-pyrazinamide as denominators. EpiCalc2000 (Gillman and Myatt) was used for the period-specific and overall rates of these events, with upper and lower 95% CIs approximated by the quadratic method [16] . Completion rates were defined as the number of cases in which patients completed rifampin-pyrazinamide therapy, compared with the number of cases in which rifampin-pyrazinamide therapy was initiated. We compared adverse event rates and treatment-completion rates between the daily and the twice-weekly regimens. All P values are 2-sided.
Historical Rates of Isoniazid-Associated Liver Injury
Our review of published data describing liver injury associated with isoniazid therapy for treatment of LTBI spanned 3 decades [17] [18] [19] [20] [21] [22] [23] [24] [25] . We emphasized reports published after 1990, because these reflect more-recent practices. ). We distributed the survey to each P p .24 of the 139 programs and providers.
RESULTS
Sampling
Response to survey. Of the 139 programs and providers, 110 (79%) responded. Respondents included local health departments (50%), local jails (20%), long-term care facilities (13%), state prisons (10%), and a range of other program types, including 3 private providers (2%). Daily isoniazid therapy administered for 9 months was offered by the greatest number of respondents, and twice-weekly rifampin-pyrazinamide therapy was offered by the fewest number (table 1) . Most programs reported some rifampin-pyrazinamide use during the survey period, but only 6.3% of their LTBI-treatment candidates received rifampin-pyrazinamide (table 2) .
Liver injury, hospitalization, death, and treatment completion. Survey findings for liver injury, hospitalization, and death associated with rifampin-pyrazinamide therapy are summarized in table 3. Between January 2000 and June 2002, the respondents reported 207 cases of patients who stopped . The changes in rates of liver injury, hospitalization, and death across the survey periods were not significant, but treatment completion rates decreased over time.
Daily versus twice-weekly rifampin-pyrazinamide therapy. Six (7%) of 87 surveyed programs reported using only twiceweekly rifampin-pyrazinamide therapy for 1041 patients (table  2) . Compared with sites that used only twice-weekly rifampinpyrazinamide therapy (among other standard regimens), the 67 sites that exclusively used daily rifampin-pyrazinamide therapy had indistinguishable rates of rifampin-pyrazinamide-associated liver injury, hospitalization, and death (table 4). Treatment completion rates were greater for the twice-weekly regimen, compared with the daily regimen ( ). P ! .001
Search for additional events. Our search of the Verispan database found reimbursement claims for rifampin and pyrazinamide (excluding other antituberculosis medications) for a total of 349 patients between 1 January 2000 and 30 April 2002. This included 227 persons in period 1, 72 in period 2, and 50 in period 3. Of the 349 patients, 48 (14%) had 133 medical claims. The ICD-9 codes for these claims showed that 3 (0.9%) of the patients had conditions related to hepatitis, liver injury, serum AST level elevations, or adverse drug effects. Patients A, B, and C had "nonspecific abnormal serum enzyme levels," "acute or unspecified hepatitis C without mention of hepatic coma," and "nonspecified elevation of transaminase," respectively.
Interviews with 3 treating physicians of patients A and B revealed that neither patient experienced a rifampin-pyrazinamide-associated adverse event. Interviews with physicians who treated patient C and a review of medical records confirmed that the patient was hospitalized for rifampin-pyrazinamideassociated liver injury, meeting the case definition. Thus, among 349 patients, 1 patient was hospitalized for rifampin-pyrazinamide-associated liver injury (hospitalization rate, 2.9 per 1000 cases; 95% CI, 0.1-18.4).
The Adverse Events Reporting System identified a single case of rifampin-pyrazinamide-associated liver injury involving hospitalization that was not detected by the other methods. The patient was a 32-year-old man who received a prescription for daily rifampin-pyrazinamide in February 2001. After 12 1 ). The 10 events from this period that were not captured by our survey stemmed from the 21% nonresponse rate of TB programs that had previously reported these cases to our passive surveillance system. The survey detected 4 additional cases (including 2 involving fatalities) not previously known to the CDC. One of these hospitalizations was reported from a TB program that did not report its denominator data, which excluded it from our rate estimates. The Verispan search accounted for 1 case, but that case was not included in our survey-based rate estimates. Eight cases occurred either before (3 cases) or after (5 cases) the survey window period. In summary, 50 cases (including 12 fatalities) were reported to the CDC through December 2004 and reflect events captured by both passive and active surveillance.
Historical rates of isoniazid-associated events. Early studies attributed hospitalization rates of up to 5.0 hospitalizations per 1000 treatment initiations and mortality rates as high as 1.0 death per 1000 treatment initiations to the use of isoniazid for treatment of LTBI [17, 19] . However, since 1991, studies involving 11 million persons treated with isoniazid for LTBI have reported hospitalization rates of 0.1-0.2 hospitalizations per 1000 treatment initiations (median, 0.15 hospitalizations per 1000 treatment initiations) and mortality rates of 0-0.3 deaths per 1000 treatment initiations (median, 0.04 deaths per 1000 treatment initiations) [21] [22] [23] [24] [25] . The highest reported isoniazid-associated hospitalization rate (0.2 hospitalizations per 1000 treatment initiations) or mortality rate (0.3 deaths per 1000 treatment initiations) and the lower limit of our 95% CIs for rifampin-pyrazinamide-associated hospitalization (1.9) and mortality rates (0.4) do not overlap. Furthermore, the lower limit of our 95% CI for rifampin-pyrazinamide-associated hospitalization rate was 9.5 times greater than the highest reported isoniazid hospitalization rate; the lower limit of our 95% CI for rifampin-pyrazinamide-associated mortality rate was 1.3 times greater than the highest reported isoniazid-associated mortality rate.
DISCUSSION
Treatment for LTBI is a distinctive component of the strategy to eliminate TB in the United States. TB elimination will be difficult to achieve without new LTBI treatments that are briefer, safer, and at least as efficacious as 9 months of isoniazid therapy [4] . In early 2000, the CDC/ATS introduced recommendations, endorsed by the Infectious Diseases Society of America, for use of rifampin-pyrazinamide therapy (independent of HIV infection) following studies involving mice [26, 27] and demonstration of safety and efficacy in 3 randomized clinical trials [5] [6] [7] . Rifampin-pyrazinamide therapy was attractive for HIVinfected patients with LTBI because it could be completed quickly, before starting treatment with antiretroviral agents. Although each rifampin-pyrazinamide clinical trial included adverse effect monitoring, no patients were hospitalized with rifampin-pyrazinamide-associated liver injury, and no hepatitis fatalities were reported. Recently, an analysis of serum transaminase monitoring from one of these trials showed that rifampin-pyrazinamide-associated liver injury was infrequent [28] . The reason for greater rates of rifampin-pyrazinamideassociated liver injury, hospitalization, and death on programmatic implementation of this regimen is unclear. A protective effect of HIV infection is conjectural, because comparable groups have not been studied in controlled trials [29] .
The 3 randomized trials had 2 limitations for detecting adverse events. The persons included in these 3 trials (all of whom were HIV-infected and most of whom were residents of developing countries) experienced substantial mortality from AIDS during follow-up: 139 (19%) [5] , 71 (18%) [6] , and 68 (19%) [7] fatalities were reported among patients treated with rifampin-pyrazinamide. Although the majority of these deaths occurred after rifampin-pyrazinamide treatment, each trial reported at least 1 death during treatment. The overall number of patients treated with rifampin-pyrazinamide in each trial was relatively limited (791, 380, and 360 patients, respectively), and deaths could have been unrecognized as being adverse events attributable to rifampin-pyrazinamide unless each death had been thoroughly investigated, particularly those deaths that occurred during the treatment period. Furthermore, an absence of severe liver injury in the 3 trials may have been a consequence of inadequate statistical power to detect this rare outcome.
After initial reports of severe liver injury associated with rifampin-pyrazinamide, some investigators asserted that such injury was less likely with the twice-weekly regimen [30, 31] . The use of a lower pyrazinamide dosage (mean dosage of 30 mg/kg twice-weekly versus a recommended dosage of 50 mg/ kg twice-weekly) used in one trial may explain a low incidence of hepatotoxicity and a high treatment-completion rate [30] . As noted by the authors of that report [30] , the efficacy of the lower pyrazinamide dosage has not been demonstrated. With 2 exceptions [30, 31] , our findings are consistent with those of reports of programmatic experiences with rifampinpyrazinamide (table 5) [32] [33] [34] [35] [36] [37] [38] [39] . The rates of treatment termination (expressed as the number of events per 1000 rifampin-pyrazinamide initiations) after either elevated AST levels 15 times the upper limit of normal or symptomatic hepatitis have been at least as high as our current estimates. In 3 reports of hospitalization for rifampin-pyrazinamide-associated liver injury [33, 36, 38] , the rates (5, 14, and 18 hospitalizations per 1000 rifampin-pyrazinamide initiations, respectively) exceed the rate estimate from our survey (3.9 hospitalizations per 1000 rifampin-pyrazinamide initiations). The lowest reported rate of elevated AST levels 15 times the upper limit of normal was among HIV-infected persons [31] . Even if rifampin-pyrazinamide were less hepatotoxic in persons infected with HIV, the risk still warrants caution; among the 12 rifampin-pyrazinamide-associated fatal liver injuries investigated by the CDC, 2 were in HIV-infected patients [10] [11] [12] .
Our strategy has limitations. First, the sampling frame we established in 2002 included few private health care providers. However, because most LTBI treatment candidates in the United States probably receive a diagnosis and are treated in the public sector, it is unlikely that numerous private-sector patients were missed. The Verispan search, which includes mostly private-sector patients, detected only 349 patients nationwide who were treated with rifampin-pyrazinamide during the surveyed period. Second, the reasons that physicians chose rifampin-pyrazinamide therapy instead of isoniazid therapy might confound the comparison of rates of liver injuries, especially if the physicians were concerned about giving isoniazid to patients who might have been more susceptible to hepatotoxicity. Finally, a major limitation of aggregate data is that patient-specific characteristics cannot be examined for their effects. Our findings provide minimal insight into mechanisms of rifampin-pyrazinamide-associated hepatoxicity. However, our rate estimates for liver injury and hospitalization were similar for the daily and twice-weekly rifampin-pyrazinamide regimens (table 3) . This is an important finding, because previous data were insufficient for this comparison.
Our survey did not pursue adverse events associated with other LTBI treatments, particularly those associated with isoniazid therapy. This was a trade-off in the survey design. Our need to balance between conducting a concise survey about rifampin-pyrazinamide treatment and conducting a more lengthy survey that would also include isoniazid therapy was debated during planning. On the basis of the pilot survey, a shorter survey designed to increase response rate prevailed. However, through publications [9] [10] [11] and presentations at meetings, the CDC requested reports of any liver injuries leading to hospitalization or death associated with all LTBI regimens. Five reports of death due to isoniazid-associated liver injury (CDC, unpublished data) were received within the same period (January 2000-June 2002) in which 10 reports of rifampin-pyrazinamide-associated deaths were received. At least 3 decades of literature describing isoniazid-associated hepatotoxicity exist, and substantially more programmatic experience with isoniazid has accumulated than with rifampin-pyrazinamide.
One wonders whether the rates of liver injury, hospitalization, and death when rifampin-pyrazinamide is used for treatment of LTBI exceed those of the combination of rifampinpyrazinamide with isoniazid for treatment of TB disease. Others have speculated on this [33] [34] [35] [36] [37] [38] [39] [40] , but there is no clear answer. It is possible that fatal liver injury associated with treatment of TB disease may occur at the same rate as it did associated with rifampin-pyrazinamide treatment of LTBI, but current surveillance systems do not allow a useful comparison.
This study and others provided the basis for the updated CDC/ATS recommendation, endorsed by the Infectious Diseases Society of America, that rifampin-pyrazinamide generally should not be used to treat LTBI, regardless of HIV-infection status [12] . The reservoir of LTBI among persons in the United States will continue to generate TB cases. Until the advent of new options that are briefer, safer, and more efficacious, 9 months of isoniazid therapy remains the preferred treatment for LTBI [40] . Adherence to this prolonged regimen for an asymptomatic condition is challenging, and this justifies the ongoing search for improvements [29, [41] [42] [43] .
